Polyprenyl immunostimulant in feline rhinotracheitis: Randomized placebo-controlled experimental and field safety studies

Alfred M. Legendre, Tanya Kuritz, Robert Heidel, Vivian M. Baylor

Research output: Contribution to journalArticle

Abstract

Feline rhinotracheitis is a ubiquitous disease caused by feline herpesvirus type 1 (FHV-1). The disease is easily transmissible and common in multi-cat environments where even vaccinated cats can develop clinical signs of respiratory or ocular disease or both when exposed to the virus. Prior to the work reported here, there was no licensed treatment for the disease on the market. We hypothesized that polyprenyl immunostimulant (PI), an immunomodulatory veterinary biologic, would be useful in treating feline rhinotracheitis by reducing the severity of respiratory or/and ocular disease. We conducted double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. Trained, masked observers applied a standardized scoring system daily in clinical examinations for 14 days after the FHV-1 challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats in 10 states, showed that PI was safe to use in cats as young as 8 weeks of age.

Original languageEnglish (US)
Article number24
JournalFrontiers in Veterinary Science
Volume4
Issue numberFEB
DOIs
StatePublished - Feb 27 2017

Fingerprint

Immunologic Adjuvants
immunostimulants
Felidae
placebos
Cats
Placebos
cats
Safety
Herpesviridae
Felid herpesvirus 1
Eye Diseases
eye diseases
Cat Diseases
Specific Pathogen-Free Organisms
Randomized Controlled Trials
clinical examination
respiratory tract diseases
disease severity
clinical trials
Viruses

All Science Journal Classification (ASJC) codes

  • veterinary(all)

Cite this

Polyprenyl immunostimulant in feline rhinotracheitis : Randomized placebo-controlled experimental and field safety studies. / Legendre, Alfred M.; Kuritz, Tanya; Heidel, Robert; Baylor, Vivian M.

In: Frontiers in Veterinary Science, Vol. 4, No. FEB, 24, 27.02.2017.

Research output: Contribution to journalArticle

@article{3e8ce1bf937c47c08e12e605540dba45,
title = "Polyprenyl immunostimulant in feline rhinotracheitis: Randomized placebo-controlled experimental and field safety studies",
abstract = "Feline rhinotracheitis is a ubiquitous disease caused by feline herpesvirus type 1 (FHV-1). The disease is easily transmissible and common in multi-cat environments where even vaccinated cats can develop clinical signs of respiratory or ocular disease or both when exposed to the virus. Prior to the work reported here, there was no licensed treatment for the disease on the market. We hypothesized that polyprenyl immunostimulant (PI), an immunomodulatory veterinary biologic, would be useful in treating feline rhinotracheitis by reducing the severity of respiratory or/and ocular disease. We conducted double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. Trained, masked observers applied a standardized scoring system daily in clinical examinations for 14 days after the FHV-1 challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats in 10 states, showed that PI was safe to use in cats as young as 8 weeks of age.",
author = "Legendre, {Alfred M.} and Tanya Kuritz and Robert Heidel and Baylor, {Vivian M.}",
year = "2017",
month = "2",
day = "27",
doi = "10.3389/fvets.2017.00024",
language = "English (US)",
volume = "4",
journal = "Frontiers in Veterinary Science",
issn = "2297-1769",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Polyprenyl immunostimulant in feline rhinotracheitis

T2 - Randomized placebo-controlled experimental and field safety studies

AU - Legendre, Alfred M.

AU - Kuritz, Tanya

AU - Heidel, Robert

AU - Baylor, Vivian M.

PY - 2017/2/27

Y1 - 2017/2/27

N2 - Feline rhinotracheitis is a ubiquitous disease caused by feline herpesvirus type 1 (FHV-1). The disease is easily transmissible and common in multi-cat environments where even vaccinated cats can develop clinical signs of respiratory or ocular disease or both when exposed to the virus. Prior to the work reported here, there was no licensed treatment for the disease on the market. We hypothesized that polyprenyl immunostimulant (PI), an immunomodulatory veterinary biologic, would be useful in treating feline rhinotracheitis by reducing the severity of respiratory or/and ocular disease. We conducted double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. Trained, masked observers applied a standardized scoring system daily in clinical examinations for 14 days after the FHV-1 challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats in 10 states, showed that PI was safe to use in cats as young as 8 weeks of age.

AB - Feline rhinotracheitis is a ubiquitous disease caused by feline herpesvirus type 1 (FHV-1). The disease is easily transmissible and common in multi-cat environments where even vaccinated cats can develop clinical signs of respiratory or ocular disease or both when exposed to the virus. Prior to the work reported here, there was no licensed treatment for the disease on the market. We hypothesized that polyprenyl immunostimulant (PI), an immunomodulatory veterinary biologic, would be useful in treating feline rhinotracheitis by reducing the severity of respiratory or/and ocular disease. We conducted double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. Trained, masked observers applied a standardized scoring system daily in clinical examinations for 14 days after the FHV-1 challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats in 10 states, showed that PI was safe to use in cats as young as 8 weeks of age.

UR - http://www.scopus.com/inward/record.url?scp=85038832077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038832077&partnerID=8YFLogxK

U2 - 10.3389/fvets.2017.00024

DO - 10.3389/fvets.2017.00024

M3 - Article

AN - SCOPUS:85038832077

VL - 4

JO - Frontiers in Veterinary Science

JF - Frontiers in Veterinary Science

SN - 2297-1769

IS - FEB

M1 - 24

ER -